Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Lenti-entry-puro Citations (1)

Originally described in: An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting.
Cao J, Wu L, Zhang SM, Lu M, Cheung WK, Cai W, Gale M, Xu Q, Yan Q Nucleic Acids Res. 2016 Nov 2;44(19):e149. Epub 2016 Jul 25.
PubMed Journal

Articles Citing Lenti-entry-puro

CRISPR activation of endogenous genes reprograms fibroblasts into cardiovascular progenitor cells for myocardial infarction therapy. Jiang L, Liang J, Huang W, Ma J, Park KH, Wu Z, Chen P, Zhu H, Ma JJ, Cai W, Paul C, Niu L, Fan GC, Wang HS, Kanisicak O, Xu M, Wang Y. Mol Ther. 2022 Jan 5;30(1):54-74. doi: 10.1016/j.ymthe.2021.10.015. Epub 2021 Oct 20. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.